Phaseline

Companies › Boehringer Ingelheim

Boehringer Ingelheim: clinical trials, targets and expected readouts

42 active drug programs in 173 registered trials: 71 Phase 1, 41 Phase 2, 35 Phase 3, 26 Phase 4; Oncology, Other, Gastroenterology, Respiratory; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Survodutide
Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist
GLP1R, GCGRPhase 3Type 2 Diabetes; Metabolic Dysfunction Associated Steatohepatitis; Metabolic Dysfunction Associated Steatohepatitis (MASH); Healthy …Dec 2026
Zongertinib
HER2 inhibitor
ERBB2Phase 3Lung Cancer, Non-squamous, Non-small Cell; Non-small Cell Lung Cancer; Solid Tumours; Healthy …Dec 2026
Empagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 3Chronic Kidney Disease; Heart Failure; Healthy; Diabetes …Dec 2026
Vicadrostat–Phase 3Heart Failure; Diabetes Mellitus, Type 2; HealthyDec 2026
Verducatib (BI 1291583)
Lysophospholipase A1 (LYPLA1) inhibitor
LYPLA1Phase 3Bronchiectasis; HealthyDec 2026
BI 690517
Finerenone-like non-steroidal mineralocorticoid receptor antagonist
NR3C4Phase 3Kidney Disease, ChronicDec 2026
Obrixtamig
DLL3-targeting antibody-drug conjugate
DLL3Phase 3Small Cell Lung Cancer (SCLC); Extrapulmonary Neuroendocrine Cancer (epNEC); Small Cell Lung Carcinoma (SCLC); Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3 …Mar 2027
Nerandomilast formulation 1
Phosphodiesterase 4 (PDE4) inhibitor
PDE4Phase 3Interstitial Lung Diseases; Idiopathic Pulmonary Fibrosis; Fibrosing Interstitial Lung Disease; Familial Pulmonary Fibrosis …Apr 2027
Tenecteplase
Tissue-type plasminogen activator exogenous protein
PLATPhase 3Acute Ischemic StrokeOct 2027
BI 764198
Sphingosine-1-phosphate receptor modulator
S1PR1Phase 3Focal Segmental Glomerulosclerosis; Proteinuric Kidney DiseasesJan 2028
BI 3000202
Type 1 interferon inhibitor
–Phase 2Systemic Lupus Erythematosus; Healthy; Type 1 InterferonopathiesDec 2026
BI 3034701–Phase 2Obesity; Healthy; OverweightDec 2026
BI 764532
DLL3-targeting antibody-drug conjugate
DLL3Phase 2Small Cell Lung Carcinoma; Small Cell Lung Carcinoma (SCLC); Glioma; Neuroendocrine NeoplasmsDec 2026
BI 1584862–Phase 2Geographic AtrophyDec 2026
BI 764524–Phase 2Diabetic RetinopathyMar 2027
BI 765423–Phase 2Idiopathic Pulmonary FibrosisMar 2027
BI 3032950–Phase 2Ulcerative ColitisJul 2027
BI 3802876–Phase 2Liver CirrhosisAug 2027
BI 1815368–Phase 2Macular EdemaMar 2028
Brigimadlin
MDM2 inhibitor
MDM2Phase 2Solid TumoursDec 2030
BI 771716–Phase 2Macular Degeneration, Age-related–
BI 765063
Immune checkpoint inhibitor antibody
–Phase 1Carcinoma, Squamous Cell of Head and Neck (HNSCC)Nov 2026
BI 770371
Checkpoint inhibitor antibody
–Phase 1Carcinoma, Squamous Cell of Head and Neck (HNSCC); Solid Tumors; Head and Neck Squamous Cell CarcinomaNov 2026
Ezabenlimab
PD-L2 inhibitor antibody
PDCD1LG2Phase 1Carcinoma, Squamous Cell of Head and Neck (HNSCC); Solid Tumors; Small Cell Lung Carcinoma (SCLC); Neoplasms …Nov 2026
BI 1701963
KRAS reactivation inhibitor
KRASPhase 1Solid Tumors, KRAS Mutation; Solid Tumors, KRAS Mutation; SOS1Nov 2026
BI 1823911
KRAS inhibitor
KRASPhase 1Solid Tumors, KRAS MutationNov 2026
BI 3776528–Phase 1HealthyFeb 2027
ATP150
Protein therapeutic (likely immunogenic protein)
–Phase 1Pancreatic Ductal AdenocarcinomaMar 2027
ATP152
Protein therapeutic (likely immunogenic protein)
–Phase 1Pancreatic Ductal AdenocarcinomaMar 2027
ATP162
Protein therapeutic (likely immunogenic protein)
–Phase 1Pancreatic Ductal AdenocarcinomaMar 2027
VSV-GP154
Oncolytic virus (vesicular stomatitis virus)
–Phase 1Pancreatic Ductal AdenocarcinomaMar 2027
BI 3812465–Phase 1Diabetic Macular EdemaMar 2027
BI 3814916–Phase 1HealthyJul 2027
BI 3804379–Phase 1HealthyFeb 2028
BI 765179–Phase 1NeoplasmsFeb 2028
BI 3819026–Phase 1Advanced Solid CancerJun 2028
BI 1703880
Immune checkpoint modulator
–Phase 1Solid TumorsSep 2028
BI 3820768
immunotherapy (immune checkpoint modulator)
–Phase 1Advanced Relapsed or Refractory Germ Cell TumoursSep 2029
BI 3810944–Phase 1Solid TumoursOct 2029
BI 3822971
Immune checkpoint inhibitor
–Phase 1Solid TumoursJan 2030
BI 3968621–Phase 1Advanced Solid TumourSep 2030
BI 3720931 (Lenticlair™-ON)
Gene therapy for cystic fibrosis
CFTRPhase 1Cystic FibrosisOct 2040

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06683053EmpagliflozinPhase 3Congestive Heart Failure (CHF)CardiovascularApr 2024
NCT06846411EmpagliflozinPhase 4DiabetesMetabolic and endocrineSep 2025
NCT06410352EmpagliflozinPhase 4Metabolic SyndromeMetabolic and endocrineSep 2025
NCT06342141EmpagliflozinPhase 2STEMICardiovascularMar 2026
NCT05510115EmpagliflozinPhase 2Polycystic Kidney, Autosomal DominantGenitourinaryMar 2026
NCT06933355EmpagliflozinPhase 4Kidney Transplantation RecipientsMetabolic and endocrineApr 2026
NCT05687058EmpagliflozinPhase 1Kidney Failure, ChronicCardiovascularMay 2026
NCT05553938EmpagliflozinPhase 1Heart FailureCardiovascularMay 2026
NCT07214818EmpagliflozinPhase 2Nephrotic SyndromeGenitourinaryJul 2026
NCT07586371EmpagliflozinPhase 2ProteinuriaMetabolic and endocrineJul 2026
NCT07774325BI 3000202Phase 1HealthyOtherOct 2026
NCT06722157BI 771716Phase 2Macular Degeneration, Age-relatedOphthalmologyOct 2026
NCT07708493BI 3034701Phase 1HealthyOtherOct 2026
NCT05068102BI 765063Phase 1Carcinoma, Squamous Cell of Head and Neck (HNSCC)OncologyNov 2026
NCT05068102BI 770371Phase 1Carcinoma, Squamous Cell of Head and Neck (HNSCC)OncologyNov 2026
NCT05068102EzabenlimabPhase 1Carcinoma, Squamous Cell of Head and Neck (HNSCC)OncologyNov 2026
NCT04973163BI 1701963Phase 1Solid Tumors, KRAS MutationOncologyNov 2026
NCT04973163BI 1823911Phase 1Solid Tumors, KRAS MutationOncologyNov 2026
NCT05182658EmpagliflozinPhase 3Hypertrophic CardiomyopathyCardiovascularNov 2026
NCT06030843EmpagliflozinPhase 2Empagliflozin in Cardiorenal Syndrome Type 1GenitourinaryNov 2026
NCT06706791EmpagliflozinPhase 4Chronic Heart FailureCardiovascularDec 2026
NCT05726032EmpagliflozinPhase 2CirrhosisGastroenterologyDec 2026
NCT07692256EmpagliflozinPhase 2Heart FailureCardiovascularDec 2026
NCT06878365BI 3000202Phase 1Type 1 InterferonopathiesImmunologyDec 2026
NCT07768813SurvodutidePhase 1HealthyMetabolic and endocrineDec 2026
NCT06151574ZongertinibPhase 3Lung Cancer, Non-squamous, Non-small CellOncologyDec 2026
NCT07845630VicadrostatPhase 1HealthyOtherDec 2026
NCT07845630EmpagliflozinPhase 1HealthyOtherDec 2026
NCT07845630EmpagliflozinPhase 1HealthyOtherDec 2026
NCT07781631Verducatib (BI 1291583)Phase 1HealthyOtherDec 2026
NCT07789028ZongertinibPhase 1HealthyOtherDec 2026
NCT05963867BI 764532Phase 1Small Cell Lung Carcinoma (SCLC)OncologyDec 2026
NCT07837648BI 3034701Phase 1HealthyOtherDec 2026
NCT05669742EmpagliflozinPhase 3Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by AntipsychoticsMetabolic and endocrineDec 2026
NCT06554301EmpagliflozinPhase 1Pulmonary Arterial HypertensionCardiovascularDec 2026
NCT07760246Verducatib (BI 1291583)Phase 1HealthyOtherDec 2026
NCT07693231BI 3034701Phase 1HealthyMetabolic and endocrineDec 2026
NCT06769048BI 1584862Phase 2Geographic AtrophyOphthalmologyDec 2026
NCT07023354Verducatib (BI 1291583)Phase 1HealthyGastroenterologyDec 2026
NCT07700940EmpagliflozinPhase 4Lupus Nephritis (LN)ImmunologyDec 2026
NCT05786443EmpagliflozinPhase 2End Stage Renal DiseaseGenitourinaryDec 2026
NCT07336797EmpagliflozinPhase 2Metabolic SyndromeInfectious diseaseDec 2026
NCT07482020EmpagliflozinPhase 2Atrial Fibrillation (AF)CardiovascularDec 2026
NCT06531824BI 690517Phase 3Kidney Disease, ChronicGenitourinaryDec 2026
NCT05671991EmpagliflozinPhase 4End Stage Renal Disease on DialysisGenitourinaryDec 2026
NCT06055452EmpagliflozinPhase 4Pre-Heart FailureCardiovascularDec 2026
NCT06989723EmpagliflozinPhase 4Type 2 DiabetesMetabolic and endocrineDec 2026
NCT06260059EmpagliflozinPhase 4Adult Congenital Heart DiseaseCardiovascularDec 2026
NCT05392764EmpagliflozinPhase 3Acute Heart FailureCardiovascularDec 2026
NCT06149793EmpagliflozinPhase 2Cystic Fibrosis-related DiabetesRespiratoryDec 2026
NCT05202353SurvodutidePhase 1ObesityMetabolic and endocrineJan 2027
NCT06745284SurvodutidePhase 1ObesityMetabolic and endocrineJan 2027
NCT06894784EmpagliflozinPhase 3Diabetes Type 1Metabolic and endocrineJan 2027
NCT07407348SurvodutidePhase 1HealthyMetabolic and endocrineJan 2027
NCT07372040EmpagliflozinPhase 2Acute Decompensated Heart FailureCardiovascularFeb 2027
NCT06745297BI 3776528Phase 1HealthyOtherFeb 2027
NCT07486102BI 3000202Phase 1HealthyGastroenterologyFeb 2027
NCT06321302BI 764524Phase 2Diabetic RetinopathyOphthalmologyMar 2027
NCT05846516ATP150Phase 1Pancreatic Ductal AdenocarcinomaOncologyMar 2027
NCT05846516ATP152Phase 1Pancreatic Ductal AdenocarcinomaOncologyMar 2027

The 60 nearest readouts of 173 trials; the rest in the app.

Targets

DLL3 (2) KRAS (2) GLP1R (1) GCGR (1) ERBB2 (1) S1PR1 (1) PDE4 (1) PDCD1LG2 (1) LYPLA1 (1) NR3C4 (1) SLC5A2 (1) PLAT (1)

Companies with the same targets

Eli Lilly Roche Novartis Beijing Biotech Revolution Medicines Jiangsu HengRui Medicine Pfizer Novo Nordisk Amgen Chia Tai Tianqing Pharmaceutical Group

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.